Curaleaf Stock May Be Undervalued Despite 71% Decline, Analysis Shows

Valuation Model Points to Upside

Simply Wall St's discounted cash flow model indicates Curaleaf shares may be undervalued at current levels. The analysis factors in projected free cash flow and a weighted average cost of capital, suggesting the stock's market price sits below the firm's calculated fair value. Curaleaf closed at CAD $4.12 on the Toronto Stock Exchange on August 27, down from a 52-week high of CAD $14.21 in October 2025.

The 71% drawdown reflects broader sector headwinds. MSOs have faced margin compression from oversupply in mature markets like Michigan and Illinois, while federal 280E tax treatment continues to inflate effective tax rates above 70% for vertically integrated operators. Curaleaf reported $343 million in revenue for Q2 2026, flat year-over-year, with adjusted EBITDA of $68 million.

Cash Flow Generation Remains Positive

Curaleaf generated $41 million in operating cash flow during the second quarter, maintaining liquidity despite capital expenditure on new dispensary builds. Seven retail locations opened in the quarter. That brought its total footprint to 151 stores. Free cash flow after capex totaled $22 million, down from $31 million in Q1 2026 but sufficient to service the company's $375 million term loan facility.

Management has prioritized debt reduction over expansion. Curaleaf retired $18 million in principal during Q2 and refinanced its senior secured notes in June, extending maturity to 2029 and reducing the coupon from 12% to 9.5%. As of June 30, the balance sheet carried $412 million in total debt against $189 million in cash and equivalents.

Margin Pressure From Wholesale Pricing

Gross margin contracted 320 basis points year-over-year to 42.1%, driven by wholesale flower pricing that fell below $1,000 per pound in several markets. Curaleaf's cultivation segment, which supplies both its own retail network and third-party dispensaries, saw average selling prices decline 18% compared to Q2 2025. It responded by idling 200,000 square feet of grow capacity in Arizona and Colorado, markets where wholesale prices dropped below cash costs of production.

Retail same-store sales declined 4% in the quarter. Illinois and Massachusetts posted double-digit declines. Florida, Curaleaf's largest market by revenue, grew 6% on a same-store basis, supported by medical patient additions and the pending adult-use ballot measure in November 2026. Florida represented 31% of total revenue in Q2.

Federal Rescheduling Timeline Still Uncertain

The DEA's proposed reclassification of cannabis to Schedule III remains under OMB review with no final rule published as of late August. If enacted, rescheduling would eliminate 280E restrictions and allow MSOs to deduct ordinary business expenses, potentially expanding Curaleaf's EBITDA margin by 800-1,000 basis points according to Stifel analyst Andrew Carter. The firm estimates Curaleaf's effective tax rate would fall from 74% to approximately 28% under Schedule III treatment.

Curaleaf hasn't provided updated guidance contingent on rescheduling. CEO Matt Darin said on the August earnings call that the company is modeling multiple scenarios but won't adjust capital allocation until a final rule is published in the Federal Register. For full background on this story, see the CannIntel topic hub on Curaleaf stock analysis.

Institutional Ownership Declined in Recent Quarter

Institutional ownership of Curaleaf shares fell to 14.2% as of June 30, down from 18.1% at year-end 2025. Hedge fund Cavalry Management exited its 4.3 million share position in Q2, while ETF provider AdvisorShares reduced its MSOS fund allocation to Curaleaf by 22%. Federal illegality of cannabis keeps the stock off-limits to most U.S. institutional investors due to its TSX listing, restricting the shareholder base primarily to retail and Canadian pension funds.

Average daily volume has thinned to 1.8 million shares, down from 3.2 million shares in early 2025. Bid-ask spreads widened to 14 basis points. That increases transaction costs for large block trades. Analysts at Canaccord Genuity noted in an August 15 report that liquidity constraints have amplified volatility and may be suppressing the stock's valuation multiple relative to U.S.-listed peers like Trulieve.

Analyst Price Targets Range Widely

Wall Street analysts maintain a median 12-month price target of CAD $7.50 for Curaleaf, implying 82% upside from current levels. Estimates range from CAD $5.00 at Needham to CAD $10.00 at Cantor Fitzgerald, reflecting divergent views on the probability and timing of federal reform. Consensus assumes Schedule III rescheduling occurs by mid-2027 and that Florida voters approve adult-use legalization in November 2026, adding an estimated $120 million in annual EBITDA to Curaleaf's Florida operations.

Bears cite execution risk. Curaleaf has missed its own guidance in three of the past four quarters, most recently in Q2 when revenue came in 6% below the midpoint of management's forecast. It also faces integration risk from its pending $240 million acquisition of Tryke Companies, a Nevada and Arizona operator, which is expected to close in Q4 2026 pending regulatory approvals.

Next catalyst: Curaleaf reports Q3 earnings on November 12. Investors will be watching Florida same-store sales trends and any updated commentary on the federal rescheduling timeline.